InCVAX – A novel strategy for treatment of late-stage, metastatic cancers through photoimmunotherapy induced tumor-specific immunity

Highlights • Laser immunotherapy (LIT) is a novel cancer treatment strategy that uses local photothermal irradiation and a local immunological stimulation. • A novel immunoadjuvant, glycated chitosan (GC), was developed to work with laser interaction to creates an in situ autologous cancer vaccine (inCVAX). • Furthermore, inCVAX has been administered in initial clinical trials for the treatment of patients with metastatic breast cancer with promising outcomes.